Considering the recent approval of treatment for ccRCCs and the potential application to other tumors related to VHL syndrome, we can hypothesize that the proposed treatment with Belzutifan plus FAK inhibitors for patients with chromosome 3p loss and chromosome 8q gain might be the best personalized approach for these patients, who have the worst prognosis, overall survival, and disease-free survival. This evidence concerns the gene PTK2 and von Hippel-Lindau disease.